Keros Therapeutics, Inc. (KROS)Healthcare | Biotechnology | Lexington, United States | NasdaqGM
11.05 USD
-0.18
(-1.603%) ⇩
(Oct. 14, 2026, 12:59 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 9:19 a.m. EDT
Keros Therapeutics presents a stark dichotomy between a fundamentally distressed biotech and a technically broken trend. The company is in a severe multi-year decline, having lost over 65% of its value since 2020, with the most recent annual return being a catastrophic -72.8%. While the balance sheet appears robust on paper with a massive current ratio of 21.96 and minimal debt relative to cash, this liquidity is likely propping up operations rather than signaling solvency in a traditional sense, given the massive operating losses and negative free cash flow. The recent news of a revenue collapse to $0.4 million and analysts cutting price targets underscores a deteriorating business reality where the core growth narrative is evaporating. The stock trades below book value, but in the biotech sector, this often signals a 'value trap' where the market has priced out the risk of failed clinical trials or commercialization hurdles. With no dividend to provide income and a statistical forecast showing almost zero expected movement over the next month, there is no compelling case for a short-term bounce or a long-term recovery until the company demonstrates sustained revenue growth or a definitive success in its pipeline milestones. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.038689 |
| MSTL | 0.081510 |
| AutoETS | 0.081863 |
| AutoTheta | 0.082209 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 46% |
| H-stat | 3.13 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.400 |
| Excess Kurtosis | -0.63 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 5.994 |
| Revenue per Share | 0.561 |
| Market Cap | 219,090,432 |
| Forward P/E | -1.67 |
| Beta | 1.12 |
| Website | https://www.kerostx.com |
As of Oct. 10, 2026, 9:19 a.m. EDT: Speculator positioning is extremely thin and lacks directional conviction. Call volume and open interest are negligible across all expirations, while put activity is similarly sparse. The lack of significant open interest at key strikes suggests no organized speculative thesis is currently forming around a specific price target, leaving the options market effectively silent on near-term catalysts.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.22498274 |
| Address1 | 1,050 Waltham Street |
| Address2 | Suite 302 |
| All Time High | 88.8 |
| All Time Low | 9.12 |
| Ask | 13.08 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.9 - Buy |
| Average Daily Volume10 Day | 182,470 |
| Average Daily Volume3 Month | 192,404 |
| Average Volume | 192,404 |
| Average Volume10Days | 182,470 |
| Beta | 1.124 |
| Bid | 7.33 |
| Bid Size | 2 |
| Board Risk | 5 |
| Book Value | 13.23 |
| City | Lexington |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 11.05 |
| Current Ratio | 21.96 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 11.29 |
| Day Low | 10.92 |
| Debt To Equity | 5.994 |
| Display Name | Keros Therapeutics |
| Dividend Yield | 0.0 |
| Earnings Timestamp | 1,785,787,200 |
| Earnings Timestamp End | 1,793,822,400 |
| Earnings Timestamp Start | 1,793,822,400 |
| Ebitda | -96,868,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.198 |
| Enterprise To Revenue | -1.28 |
| Enterprise Value | -19,222,678 |
| Eps Current Year | -5.22 |
| Eps Forward | -6.616 |
| Eps Trailing Twelve Months | -3.22 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 11.1245 |
| Fifty Day Average Change | -0.074500084 |
| Fifty Day Average Change Percent | -0.0066969376 |
| Fifty Two Week Change Percent | -22.498274 |
| Fifty Two Week High | 22.55 |
| Fifty Two Week High Change | -11.499999 |
| Fifty Two Week High Change Percent | -0.5099778 |
| Fifty Two Week Low | 9.69 |
| Fifty Two Week Low Change | 1.3600006 |
| Fifty Two Week Low Change Percent | 0.14035095 |
| Fifty Two Week Range | 9.69 - 22.55 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,586,352,600,000 |
| Float Shares | 17,770,117 |
| Forward Eps | -6.616 |
| Forward P E | -1.6701934 |
| Free Cashflow | -27,174,500 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 92 |
| Fullday Change | -0.17999935 |
| Fullday Change Percent | -1.6028438 |
| Fullday Price | 11.05 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.0 |
| Gross Profits | -58,345,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.03964 |
| Held Percent Institutions | 0.95312 |
| Implied Shares Outstanding | 19,827,188 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis. The company has collaboration and license agreements with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept; and Takeda Pharmaceuticals U.S.A., Inc. to develop, manufacture, and commercialize elritercept and certain derivative compounds. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts. |
| Long Name | Keros Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 219,090,432 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_333195513 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -83,159,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 230,590,196 |
| Number Of Analyst Opinions | 6 |
| Open | 11.07 |
| Operating Cashflow | -47,993,000 |
| Operating Margins | -6.55841 |
| Overall Risk | 6 |
| Payout Ratio | 0.0 |
| Phone | 617 314 6297 |
| Previous Close | 11.23 |
| Price Eps Current Year | -2.1168582 |
| Price Hint | 2 |
| Price To Book | 0.835223 |
| Price To Sales Trailing12 Months | 14.592409 |
| Profit Margins | 0.0 |
| Quick Ratio | 21.469 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.85714 |
| Region | US |
| Regular Market Change | -0.17999935 |
| Regular Market Change Percent | -1.6028438 |
| Regular Market Day High | 11.29 |
| Regular Market Day Low | 10.92 |
| Regular Market Day Range | 10.92 - 11.29 |
| Regular Market Open | 11.07 |
| Regular Market Previous Close | 11.23 |
| Regular Market Price | 11.05 |
| Regular Market Time | 1,791,997,157 |
| Regular Market Volume | 59,728 |
| Return On Assets | -0.11781 |
| Return On Equity | -0.17163 |
| Revenue Per Share | 0.561 |
| Sand P52 Week Change | 0.17004645 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 7 |
| Shares Outstanding | 19,827,188 |
| Shares Percent Shares Out | 0.058000002 |
| Shares Short | 1,149,418 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 1,165,086 |
| Short Name | Keros Therapeutics, Inc. |
| Short Percent Of Float | 0.066700004 |
| Short Ratio | 6.41 |
| Source Interval | 15 |
| State | MA |
| Symbol | KROS |
| Target High Price | 25.0 |
| Target Low Price | 16.0 |
| Target Mean Price | 19.83333 |
| Target Median Price | 19.0 |
| Total Cash | 257,606,000 |
| Total Cash Per Share | 12.993 |
| Total Debt | 15,724,000 |
| Total Revenue | 15,014,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.22 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 12.58815 |
| Two Hundred Day Average Change | -1.5381498 |
| Two Hundred Day Average Change Percent | -0.122190304 |
| Type Disp | Equity |
| Volume | 59,728 |
| Website | https://www.kerostx.com |
| Zip | 2,421 |